Cancer

• EMA guidance · 2016-02-02
  How to facilitate development of cancer immunotherapies

  EMA guidance outlining considerations to facilitate the development of cancer immunotherapies, including design, translational science, and …

• EMA guidance · 2007-10-23
  Public Statement: Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease

  EMA public statement warning about risks associated with epoetins, including tumor progression, thromboembolic events in cancer patients, an…